UBA7

Last update 08 May 2025

Basic Info

Synonyms

D8, UBA1B, UBA7

+ [6]

Introduction

E1-activating enzyme that catalyzes the covalent conjugation of the ubiquitin-like protein product of ISG15 to additional interferon stimulated proteins (ISGs) as well as other cellular proteins such as P53 in a process termed protein ISGylation (PubMed:27545325). Plays an essential role in antiviral immunity together with ISG15 by restricting the replication of many viruses including rabies virus, influenza virus, sindbis virus, rotavirus or human cytomegalovirus (PubMed:16254333, PubMed:19073728, PubMed:29056542, PubMed:29743376, PubMed:37722521). For example, ISG15 modification of influenza A protein NS1 disrupts the association of the NS1 with importin-alpha leading to NS1 nuclear import inhibition (PubMed:20133869). ISGylation of human cytomegalovirs protein UL26 regulates its stability and inhibits its activities to suppress NF-kappa-B signaling (PubMed:27564865).

100 Clinical Results associated with UBA7

100 Translational Medicine associated with UBA7

0 Patents (Medical) associated with UBA7

401

Literatures (Medical) associated with UBA7

31 Dec 2025·Journal of Enzyme Inhibition and Medicinal Chemistry

Identification of novel inhibitors of dengue viral NS5 RNA-dependent RNA polymerase through molecular docking, biological activity evaluation and molecular dynamics simulations

Article

Author: Zhang, Susu ; Zong, Keli ; Li, Wei ; Cao, Ruiyuan ; Yan, Hong ; Wei, Chaochun ; Liu, Xiaojing ; Wang, Cong ; Li, Xingzhou ; Ruan, Jiajun

The DENV-NS5 RNA-dependent RNA polymerase (RdRp) is essential for viral replication, and one of the targets of anti-virus. In this study, the Uni-VSW module was used to virtual screen 1.6 million compounds in the ChemDiv and TargetMol (USA) database, 27 candidates were obtained. Thereby 23 candidates were selected based on their binding free energies by 50 ns MD simulations. The biological activity of the candidates and the reference compounds (BCX4430 and Compound 27) were evaluated on their IC₅₀ values against DENV-NGC, CC₅₀ values, and selectivity index. Among these, the IC₅₀ values of D1 and D8 were 13.06 ± 1.17 μM and 14.79 ± 7.76 μM, respectively, which were better than that of Compound 27 (IC₅₀ =19.67 ± 1.12 μM). The comprehensive MD simulations were performed on the candidates to assess the stability behaviour and binding mechanisms. The density functional theory (DFT) analysis was also conducted to explore the structural and electronic properties.

06 Apr 2025·Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

[The investigation and spatio-temporal analysis of first importation associated D8 genotype measles case in a child, Shandong Province, 2023].

Article

Author: Liu, D C ; Xu, A Q ; Zhang, L ; Tao, Z X ; Liu, Y ; Guo, S Z ; Wang, S T ; Xu, Q

Objective: To analyze the epidemiological, etiological characteristics and transmission of an imported D8 genotype measles case in a child in Shandong Province, August 2023. Methods: A study was conducted on a measles case and 16 contacts in Shandong Province in August 2023. Field epidemiological surveys, including recent exposure and immunization history, were conducted. Serum and throat swab samples were collected from all 16 subjects. Measles IgM and IgG antibody levels and avidity were measured by ELISA, while virus detection and genotyping were performed using fluorescence quantitative PCR and RT-PCR. Genetic evolutionary analysis of the obtained sequences was conducted using MEGA and Beast software. Results: The case was an 11-year-old boy, a fifth-grade student, who developed symptoms on August 28, 2023. A total of five close contacts were investigated, including three family members (grandfather, father and sister) and two playmates. Additionally, 11 classmates who had close contact with the case's sister during the infectious period (within five days after the rash onset) were also investigated. Among the 16 serum samples tested, only one case was positive for IgM, while the other 15 samples were negative for IgM. The results of the serum antibody avidity test showed that among the 16 serum samples, 14 were positive for IgG. Of these, eight had a relative avidity index >55%, indicating high-avidity antibodies; one had a relative avidity index <45%, indicating low-avidity antibodies; and five had an avidity index between 45% and 55%. The IgG detection OD values for the case's sister and grandfather were higher than those of the other contacts. Based on the vaccination history of the subjects and the results of IgM and IgG tests, it was preliminarily determined that the case had a recent wild-type measles virus infection. The case's sister and grandfather had a history of measles wild-type virus infection, while the high-avidity antibodies in the other contacts were likely induced by the measles vaccine. The results of the pharyngeal swab tests showed that only the case was positive for measles virus nucleic acid, while the remaining 15 samples were negative for measles virus. The genetic evolutionary analysis revealed that the viral sequence of this case (Mvs/Shandong.CHN/38.23) had a 100% homology with the Hong Kong strain sequence from August 2023. It belonged to a different transmission chain from the D8 genotype strains that appeared in Shandong Province between 2018 and 2019, with sequence homology ranging from 98.0% to 98.8%. The sequence homology within the transmission chain of this case was between 99.1% and 100%. The evolutionary rate of this transmission chain was approximately 8.38×10^-3 sub/site/year, and the most recent common ancestor was estimated to have emerged around the year 2011. Conclusion: This case is the first imported D8 genotype measles case in Shandong Province. There is no spatio-temporal correlation between this case and adult cases of D8 genotype imported from Shandong Province in 2018-2019, indicating a new D8 genotype imported epidemic.

01 Feb 2025·eJHaem

Real‐world characteristics and outcomes of patients with multiple myeloma receiving second‐line treatment in England

Article

Author: Yong, Kwee ; Cornic, Laura ; Crossman‐Barnes, Christina‐Jane ; Jose, Sophie ; Woods, Philip ; Moore, Sally ; Khalaf, Zeyad ; Soutar, Megan

AbstractIntroductionDespite recent advances in first‐line therapies for multiple myeloma (MM), most patients relapse or become refractory, underscoring the need for effective second‐line (2L) regimens for relapsed/refractory MM (RRMM).MethodsThis study describes the real‐world baseline characteristics, treatment patterns and clinical outcomes of adult patients diagnosed with MM between 2013 and 2020 using data collated by the National Cancer Registration and Analysis Service (NCRAS) of the National Health Service in England. The study cohorts were broadly aligned to the eligibility criteria of the ongoing DREAMM‐7 (D7) and DREAMM‐8 (D8) clinical trials. We focus on lenalidomide‐exposed/refractory patients who received daratumumab–bortezomib–dexamethasone (DaraVd) at 2L in both cohorts.ResultsIn the D7‐like cohort, the lenalidomide‐exposed (n = 282) and lenalidomide‐refractory (n = 143) patients who received DaraVd at 2L had a median (95% confidence interval [CI]) time to next treatment or death (TTNTD) of 15.1 (12.6–22.4) and 10.3 (7.4–13.9) months, respectively. In the D8‐like cohort, the lenalidomide‐exposed (n = 269) and lenalidomide‐refractory (n = 148) patients who received DaraVd at 2L had a median (95% CI) TTNTD of 14.5 (11.7–19.7) and 10.0 (7.3–13.7) months, respectively.ConclusionPatients with RRMM in England receiving DaraVd at 2L have poor clinical outcomes, highlighting the urgent need for new therapies, particularly for lenalidomide‐refractory patients.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

UBA7

Basic Info

Related

Analysis